Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cancer and Metastasis Reviews
Erschienen in: Cancer and Metastasis Reviews 1/2014

01.03.2014 | NON-THEMATIC REVIEW

GAP-independent functions of DLC1 in metastasis

verfasst von: David Barras, Christian Widmann

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Metastases are responsible for most cancer-related deaths. One of the hallmarks of metastatic cells is increased motility and migration through extracellular matrixes. These processes rely on specific small GTPases, in particular those of the Rho family. Deleted in liver cancer-1 (DLC1) is a tumor suppressor that bears a RhoGAP activity. This protein is lost in most cancers, allowing malignant cells to proliferate and disseminate in a Rho-dependent manner. However, DLC1 is also a scaffold protein involved in alternative pathways leading to tumor and metastasis suppressor activities. Recently, substantial information has been gathered on these mechanisms and this review is aiming at describing the potential and known alternative GAP-independent mechanisms allowing DLC1 to impair migration, invasion, and metastasis formation.
Literatur
1.
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011). Global cancer statistics. CA: A Cancer Journal for Clinicians, 61(2), 69–90.
2.
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674.PubMedCrossRef
3.
Chiang, A. C., & Massague, J. (2008). Molecular basis of metastasis. New England Journal of Medicine, 359(26), 2814–2823.PubMedCrossRef
4.
Pollard, T. D., & Borisy, G. G. (2003). Cellular motility driven by assembly and disassembly of actin filaments. Cell, 112(4), 453–465.PubMedCrossRef
5.
Mitra, S. K., Hanson, D. A., & Schlaepfer, D. D. (2005). Focal adhesion kinase: in command and control of cell motility. Nature Reviews Molecular Cell Biology, 6(1), 56–68.PubMedCrossRef
6.
Geiger, B., Bershadsky, A., Pankov, R., & Yamada, K. M. (2001). Transmembrane crosstalk between the extracellular matrix–cytoskeleton crosstalk. Nature Reviews Molecular Cell Biology, 2(11), 793–805.PubMedCrossRef
7.
Grise, F., Bidaud, A., & Moreau, V. (2009). Rho GTPases in hepatocellular carcinoma. Biochimica et Biophysica Acta, 1795(2), 137–151.PubMed
8.
Etienne-Manneville, S., & Hall, A. (2002). Rho GTPases in cell biology. Nature, 420(6916), 629–635.PubMedCrossRef
9.
Ridley, A. J. (2001). Rho GTPases and cell migration. Journal of Cell Science, 114(15), 2713–2722.PubMed
10.
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007). GEFs and GAPs: critical elements in the control of small G proteins. Cell, 129(5), 865–877.PubMedCrossRef
11.
Tcherkezian, J., & Lamarche-Vane, N. (2007). Current knowledge of the large RhoGAP family of proteins. Biology of the Cell, 99(2), 67–86.PubMedCrossRef
12.
13.
Durkin, M. E., Yuan, B. Z., Zhou, X., Zimonjic, D. B., Lowy, D. R., Thorgeirsson, S. S., et al. (2007). DLC-1:a Rho GTPase-activating protein and tumour suppressor. Journal of Cellular and Molecular Medicine, 11(5), 1185–1207.PubMedCrossRef
14.
Xue, W., Krasnitz, A., Lucito, R., Sordella, R., Vanaelst, L., Cordon-Cardo, C., et al. (2008). DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes and Development, 22(11), 1439–1444.PubMedCentralPubMedCrossRef
15.
Liao, Y. C., & Lo, S. H. (2008). Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver. International Journal of Biochemistry and Cell Biology, 40(5), 843–847.PubMedCentralPubMedCrossRef
16.
Lukasik, D., Wilczek, E., Wasiutynski, A., & Gornicka, B. (2011). Deleted in liver cancer protein family in human malignancies (Review). Oncology Letters, 2(5), 763–768.PubMedCentralPubMed
17.
El-Sitt, S., & El-Sibai, M. (2013). The STAR of the DLC family. Journal of Receptor and Signal Transduction Research, 33(1), 10–13.PubMedCrossRef
18.
Kim, T. Y., Vigil, D., Der, C. J., & Juliano, R. L. (2009). Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility. Cancer and Metastasis Reviews, 28(1–2), 77–83.PubMedCentralPubMedCrossRef
19.
Feng, X., Li, C., Liu, W., Chen, H., Zhou, W., Wang, L., et al. (2013). DLC-1, a candidate tumor suppressor gene, inhibits the proliferation, migration and tumorigenicity of human nasopharyngeal carcinoma cells. International Journal of Oncology, 42(6), 1973–1984.PubMed
20.
Wu, P. P., Jin, Y. L., Shang, Y. F., Jin, Z., Wu, P., & Huang, P. L. (2009). Restoration of DLC1 gene inhibits proliferation and migration of human colon cancer HT29 cells. Annals of Clinical and Laboratory Science, 39(3), 263–269.PubMed
21.
Heering, J., Erlmann, P., & Olayioye, M. A. (2009). Simultaneous loss of the DLC1 and PTEN tumor suppressors enhances breast cancer cell migration. Experimental Cell Research, 315(15), 2505–2514.PubMedCrossRef
22.
Kim, T. Y., Healy, K. D., Der, C. J., Sciaky, N., Bang, Y. J., & Juliano, R. L. (2008). Effects of structure of Rho GTPase-activating protein DLC-1 on cell morphology and migration. Journal of Biological Chemistry, 283(47), 32762–32770.PubMedCentralPubMedCrossRef
23.
Wong, C. M., Yam, J. W., Ching, Y. P., Yau, T. O., Leung, T. H., Jin, D. Y., et al. (2005). Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Research, 65(19), 8861–8868.PubMedCrossRef
24.
Ullmannova-Benson, V., Guan, M., Zhou, X., Tripathi, V., Yang, X. Y., Zimonjic, D. B., et al. (2009). DLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathway. Leukemia, 23(2), 383–390.PubMedCentralPubMedCrossRef
25.
Goodison, S., Yuan, J., Sloan, D., Kim, R., Li, C., Popescu, N. C., et al. (2005). The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Research, 65(14), 6042–6053.PubMedCentralPubMedCrossRef
26.
Healy, K. D., Hodgson, L., Kim, T. Y., Shutes, A., Maddileti, S., Juliano, R. L., et al. (2008). DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms. Molecular Carcinogenesis, 47(5), 326–337.PubMedCentralPubMedCrossRef
27.
Zhou, X., Zimonjic, D. B., Park, S. W., Yang, X. Y., Durkin, M. E., & Popescu, N. C. (2008). DLC1 suppresses distant dissemination of human hepatocellular carcinoma cells in nude mice through reduction of RhoA GTPase activity, actin cytoskeletal disruption and down-regulation of genes involved in metastasis. International Journal of Oncology, 32(6), 1285–1291.PubMed
28.
Yau, T. O., Leung, T. H., Lam, S., Cheung, O. F., Tung, E. K., Khong, P. L., et al. (2009). Deleted in liver cancer 2 (DLC2) was dispensable for development and its deficiency did not aggravate hepatocarcinogenesis. PLoS One, 4(8), e6566.PubMedCentralPubMedCrossRef
29.
Homma, Y., & Emori, Y. (1995). A dual functional signal mediator showing RhoGAP and phospholipase C-δ stimulating activities. EMBO Journal, 14(2), 286–291.PubMedCentralPubMed
30.
Yuan, B. Z., Miller, M. J., Keck, C. L., Zimonjic, D. B., Thorgeirsson, S. S., & Popescu, N. C. (1998). Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Research, 58(10), 2196–2199.PubMed
31.
Durkin, M. E., Yuan, B. Z., Thorgeirsson, S. S., & Popescu, N. C. (2002). Gene structure, tissue expression, and linkage mapping of the mouse DLC-1 gene (Arhgap7). Gene, 288(1–2), 119–127.PubMedCrossRef
32.
Qian, X., Durkin, M. E., Wang, D., Tripathi, B. K., Olson, L., Yang, X. Y., et al. (2012). Inactivation of the Dlc1 gene cooperates with downregulation of p15INK4b and p16Ink4a, leading to neoplastic transformation and poor prognosis in human cancer. Cancer Research, 72(22), 5900–5911.PubMedCrossRef
33.
Yuan, B. Z., Zhou, X., Durkin, M. E., Zimonjic, D. B., Gumundsdottir, K., Eyfjord, J. E., et al. (2003). DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Oncogene, 22(3), 445–450.PubMedCrossRef
34.
Sahai, E., Olson, M. F., & Marshall, C. J. (2001). Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. EMBO Journal, 20(4), 755–766.PubMedCentralPubMedCrossRef
35.
Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Kakonen, S. M., Cordon-Cardo, C., et al. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell, 3(6), 537–549.PubMedCrossRef
36.
Matsuyama, H., Pan, Y., Oba, K., Yoshihiro, S., Matsuda, K., Hagarth, L., et al. (2001). Deletions on chromosome 8p22 may predict disease progression as well as pathological staging in prostate cancer. Clinical Cancer Research, 7(10), 3139–3143.PubMed
37.
Wilson, P. J., McGlinn, E., Marsh, A., Evans, T., Arnold, J., Wright, K., et al. (2000). Sequence variants of DLC1 in colorectal and ovarian tumours. Human Mutation, 15(2), 156–165.PubMedCrossRef
38.
Yuan, B. Z., Durkin, M. E., & Popescu, N. C. (2003). Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers. Cancer Genetics and Cytogenetics, 140(2), 113–117.PubMedCrossRef
39.
Guan, M., Zhou, X., Soulitzis, N., Spandidos, D. A., & Popescu, N. C. (2006). Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Clinical Cancer Research, 12(5), 1412–1419.PubMedCrossRef
40.
Scholz, R. P., Regner, J., Theil, A., Erlmann, P., Holeiter, G., Jahne, R., et al. (2009). DLC1 interacts with 14-3-3 proteins to inhibit RhoGAP activity and block nucleocytoplasmic shuttling. Journal of Cell Science, 122(1), 92–102.PubMedCrossRef
41.
Scholz, R. P., Gustafsson, J. O., Hoffmann, P., Jaiswal, M., Ahmadian, M. R., Eisler, S. A., et al. (2011). The tumor suppressor protein DLC1 is regulated by PKD-mediated GAP domain phosphorylation. Experimental Cell Research, 317(4), 496–503.PubMedCrossRef
42.
Ko, F. C., Chan, L. K., Tung, E. K., Lowe, S. W., Ng, I. O., & Yam, J. W. (2010). Akt phosphorylation of deleted in liver cancer 1 abrogates its suppression of liver cancer tumorigenesis and metastasis. Gastroenterology, 139(4), 1397–1407.PubMedCrossRef
43.
Ko, F. C., Chan, L. K., Man-Fong, S. K., Yeung, Y. S., Yuk-Ting, T. E., Lu, P., et al. (2013). PKA-induced dimerization of the RhoGAP DLC1 promotes its inhibition of tumorigenesis and metastasis. Nature Communications, 41618.
44.
Zhong, D., Zhang, J., Yang, S., Soh, U. J., Buschdorf, J. P., Zhou, Y. T., et al. (2009). The SAM domain of the RhoGAP DLC1 binds EF1A1 to regulate cell migration. Journal of Cell Science, 122(3), 414–424.PubMedCrossRef
45.
Kim, C. A., & Bowie, J. U. (2003). SAM domains: uniform structure, diversity of function. Trends in Biochemical Sciences, 28(12), 625–628.PubMedCrossRef
46.
Li, G., Du, X., Vass, W. C., Papageorge, A. G., Lowy, D. R., & Qian, X. (2011). Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK). Proceedings of the National Academy of Sciences of the United States of America, 108(41), 17129–17134.PubMedCentralPubMedCrossRef
47.
Sekimata, M., Kabuyama, Y., Emori, Y., & Homma, Y. (1999). Morphological changes and detachment of adherent cells induced by p122, a GTPase-activating protein for Rho. Journal of Biological Chemistry, 274(25), 17757–17762.PubMedCrossRef
48.
Clark, B. J. (2012). The mammalian START domain protein family in lipid transport in health and disease. Journal of Endocrinology, 212(3), 257–275.PubMedCrossRef
49.
Friedl, P., & Wolf, K. (2003). Tumour-cell invasion and migration: diversity and escape mechanisms. Nature Reviews Cancer, 3(5), 362–374.PubMedCrossRef
50.
Holeiter, G., Heering, J., Erlmann, P., Schmid, S., Jahne, R., & Olayioye, M. A. (2008). Deleted in liver cancer 1 controls cell migration through a Dia1-dependent signaling pathway. Cancer Research, 68(21), 8743–8751.PubMedCrossRef
51.
Jin, Y., Tian, X., Shang, Y., & Huang, P. (2008). Inhibition of DLC-1 gene expression by RNA interference in the colon cancer LoVo cell line. Oncology Reports, 19(3), 669–674.PubMed
52.
Shih, Y. P., Takada, Y., & Lo, S. H. (2012). Silencing of DLC1 upregulates PAI-1 expression and reduces migration in normal prostate cells. Molecular Cancer Research, 10(1), 34–39.PubMedCentralPubMedCrossRef
53.
Durkin, M. E., Avner, M. R., Huh, C. G., Yuan, B. Z., Thorgeirsson, S. S., & Popescu, N. C. (2005). DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development. FEBS Letters, 579(5), 1191–1196.PubMedCrossRef
54.
Franz, C. M., Jones, G. E., & Ridley, A. J. (2002). Cell migration in development and disease. Developmental Cell, 2(2), 153–158.PubMedCrossRef
55.
Pilz, D., Stoodley, N., & Golden, J. A. (2002). Neuronal migration, cerebral cortical development, and cerebral cortical anomalies. Journal of Neuropathology and Experimental Neurology, 61(1), 1–11.PubMed
56.
Cramer L.P. (2013). Mechanism of cell rear retraction in migrating cells. Current Opinion in Cell Biology 25:591–599.
57.
58.
Nobes, C. D., & Hall, A. (1999). Rho GTPases control polarity, protrusion, and adhesion during cell movement. Journal of Cell Biology, 144(6), 1235–1244.PubMedCentralPubMedCrossRef
59.
Ridley, A. J., & Hall, A. (1992). The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell, 70(3), 389–399.PubMedCrossRef
60.
Takaishi, K., Kikuchi, A., Kuroda, S., Kotani, K., Sasaki, T., & Takai, Y. (1993). Involvement of rho p21 and its inhibitory GDP/GTP exchange protein (rho GDI) in cell motility. Molecular and Cellular Biology, 13(1), 72–79.PubMedCentralPubMed
61.
Monnier, Y., Farmer, P., Bieler, G., Imaizumi, N., Sengstag, T., Alghisi, G. C., et al. (2008). CYR61 and αVβ5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Research, 68(18), 7323–7331.PubMedCrossRef
62.
Yilmaz, M., & Christofori, G. (2009). EMT, the cytoskeleton, and cancer cell invasion. Cancer and Metastasis Reviews, 28(1–2), 15–33.PubMedCrossRef
63.
Perl, A. K., Wilgenbus, P., Dahl, U., Semb, H., & Christofori, G. (1998). A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature, 392(6672), 190–193.PubMedCrossRef
64.
Banyard, J., Anand-Apte, B., Symons, M., & Zetter, B. R. (2000). Motility and invasion are differentially modulated by Rho family GTPases. Oncogene, 19(4), 580–591.PubMedCrossRef
65.
Sahai, E., & Marshall, C. J. (2002). RHO-GTPases and cancer. Nature Reviews Cancer, 2(2), 133–142.PubMedCrossRef
66.
Yoshioka, K., Nakamori, S., & Itoh, K. (1999). Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells. Cancer Research, 59(8), 2004–2010.PubMed
67.
Wheeler, A. P., & Ridley, A. J. (2004). Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. Experimental Cell Research, 301(1), 43–49.PubMedCrossRef
68.
Liu, A. X., Rane, N., Liu, J. P., & Prendergast, G. C. (2001). RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells. Molecular and Cellular Biology, 21(20), 6906–6912.PubMedCentralPubMedCrossRef
69.
Hakem, A., Sanchez-Sweatman, O., You-Ten, A., Duncan, G., Wakeham, A., Khokha, R., et al. (2005). RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes and Development, 19(17), 1974–1979.PubMedCentralPubMedCrossRef
70.
Clark, E. A., Golub, T. R., Lander, E. S., & Hynes, R. O. (2000). Genomic analysis of metastasis reveals an essential role for RhoC. Nature, 406(6795), 532–535.PubMedCrossRef
71.
Iiizumi, M., Bandyopadhyay, S., Pai, S. K., Watabe, M., Hirota, S., Hosobe, S., et al. (2008). RhoC promotes metastasis via activation of the Pyk2 pathway in prostate cancer. Cancer Research, 68(18), 7613–7620.PubMedCentralPubMedCrossRef
72.
Bishop, A. L., & Hall, A. (2000). Rho GTPases and their effector proteins. Biochemistry Journal, 348(2), 2241–2255.CrossRef
73.
Matsui, T., Amano, M., Yamamoto, T., Chihara, K., Nakafuku, M., Ito, M., et al. (1996). Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO Journal, 15(9), 2208–2216.PubMedCentralPubMed
74.
Chesarone, M. A., DuPage, A. G., & Goode, B. L. (2010). Unleashing formins to remodel the actin and microtubule cytoskeletons. Nature Reviews Molecular Cell Biology, 11(1), 62–74.PubMedCrossRef
75.
Raftopoulou, M., & Hall, A. (2004). Cell migration: Rho GTPases lead the way. Developments in Biologicals, 265(1), 23–32.CrossRef
76.
Palazzo, A. F., Joseph, H. L., Chen, Y. J., Dujardin, D. L., Alberts, A. S., Pfister, K. K., et al. (2001). Cdc42, dynein, and dynactin regulate MTOC reorientation independent of Rho-regulated microtubule stabilization. Current Biology, 11(19), 1536–1541.PubMedCrossRef
77.
Reymond, N., Im, J. H., Garg, R., Vega, F. M., Borda, D. B., Riou, P., et al. (2012). Cdc42 promotes transendothelial migration of cancer cells through β1 integrin. Journal of Cell Biology, 199(4), 653–668.PubMedCentralPubMedCrossRef
78.
Wong, C. C., Wong, C. M., Ko, F. C., Chan, L. K., Ching, Y. P., Yam, J. W., et al. (2008). Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma. PLoS One, 3(7), e2779.PubMedCentralPubMedCrossRef
79.
Ishizaki, T., Uehata, M., Tamechika, I., Keel, J., Nonomura, K., Maekawa, M., et al. (2000). Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Molecular Pharmacology, 57(5), 976–983.PubMed
80.
Tripathi, V., Popescu, N. C., & Zimonjic, D. B. (2012). DLC1 interaction with α-catenin stabilizes adherens junctions and enhances DLC1 antioncogenic activity. Molecular and Cellular Biology, 32(11), 2145–2159.PubMedCentralPubMedCrossRef
81.
Harris, T. J., & Tepass, U. (2010). Adherens junctions: from molecules to morphogenesis. Nature Reviews Molecular Cell Biology, 11(7), 502–514.PubMedCrossRef
82.
Desai, R., Sarpal, R., Ishiyama, N., Pellikka, M., Ikura, M., & Tepass, U. (2013). Monomeric α-catenin links cadherin to the actin cytoskeleton. Nature Cell Biology, 15(3), 261–273.PubMedCrossRef
83.
Kobielak, A., & Fuchs, E. (2004). α-catenin: at the junction of intercellular adhesion and actin dynamics. Nature Reviews Molecular Cell Biology, 5(8), 614–625.PubMedCentralPubMedCrossRef
84.
Tripathi V., Popescu N.C. & Zimonjic D.B. (2013). DLC1 induces expression of E-cadherin in prostate cancer cells through Rho pathway and suppresses invasion. Oncogene. doi:10.​1038/​onc.​2013.​7.
85.
Yam, J. W., Ko, F. C., Chan, C. Y., Jin, D. Y., & Ng, I. O. (2006). Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. Cancer Research, 66(17), 8367–8372.PubMedCrossRef
86.
Qian, X., Li, G., Asmussen, H. K., Asnaghi, L., Vass, W. C., Braverman, R., et al. (2007). Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. Proceedings of the National Academy of Sciences of the United States of America, 104(21), 9012–9017.PubMedCentralPubMedCrossRef
87.
Liao, Y. C., Si, L., deVere White, R. W., & Lo, S. H. (2007). The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1. Journal of Cell Biology, 176(1), 43–49.PubMedCentralPubMedCrossRef
88.
Cao, X., Voss, C., Zhao, B., Kaneko, T., & Li, S. S. (2012). Differential regulation of the activity of deleted in liver cancer 1 (DLC1) by tensins controls cell migration and transformation. Proceedings of the National Academy of Sciences of the United States of America, 109(5), 1455–1460.PubMedCentralPubMedCrossRef
89.
Yang, X., Popescu, N. C., & Zimonjic, D. B. (2011). DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism. Cancer Research, 71(8), 2916–2925.PubMedCentralPubMedCrossRef
90.
Du, X., Qian, X., Papageorge, A., Schetter, A. J., Vass, W. C., Liu, X., et al. (2012). Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells. Cancer Research, 72(17), 4405–4416.PubMedCrossRef
91.
Yang, X. Y., Guan, M., Vigil, D., Der, C. J., Lowy, D. R., & Popescu, N. C. (2009). p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities. Oncogene, 28(11), 1401–1409.PubMedCentralPubMedCrossRef
92.
Yin, H. L., & Janmey, P. A. (2003). Phosphoinositide regulation of the actin cytoskeleton. Annual Review of Physiology, 65(65), 761–789.PubMedCrossRef
93.
Raucher, D., Stauffer, T., Chen, W., Shen, K., Guo, S., York, J. D., et al. (2000). Phosphatidylinositol 4,5-bisphosphate functions as a second messenger that regulates cytoskeleton-plasma membrane adhesion. Cell, 100(2), 221–228.PubMedCrossRef
94.
Toker, A. (1998). The synthesis and cellular roles of phosphatidylinositol 4,5-bisphosphate. Current Opinion in Cell Biology, 10(2), 254–261.PubMedCrossRef
95.
Kawai, K., Yamaga, M., Iwamae, Y., Kiyota, M., Kamata, H., Hirata, H., et al. (2004). A PLCδ1-binding protein, p122RhoGAP, is localized in focal adhesions. Biochemical Society Transactions, 32(6), 1107–1109.PubMedCrossRef
96.
Xiang, T., Li, L., Fan, Y., Jiang, Y., Ying, Y., Putti, T. C., et al. (2010). PLCD1 is a functional tumor suppressor inducing G(2)/M arrest and frequently methylated in breast cancer. Cancer Biology and Therapy, 10(5), 520–527.PubMedCrossRef
97.
Liao, Y. C., Shih, Y. P., & Lo, S. H. (2008). Mutations in the focal adhesion targeting region of deleted in liver cancer-1 attenuate their expression and function. Cancer Research, 68(19), 7718–7722.PubMedCentralPubMedCrossRef
98.
Kawai, K., Iwamae, Y., Yamaga, M., Kiyota, M., Ishii, H., Hirata, H., et al. (2009). Focal adhesion-localization of START-GAP1/DLC1 is essential for cell motility and morphology. Genes to Cells, 14(2), 227–241.PubMedCrossRef
99.
Chan, L. K., Ko, F. C., Ng, I. O., & Yam, J. W. (2009). Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function. PLoS One, 4(5), e5572.PubMedCentralPubMedCrossRef
100.
Chan, L. K., Ko, F. C., Sze, K. M., Ng, I. O., & Yam, J. W. (2011). Nuclear-targeted deleted in liver cancer 1 (DLC1) is less efficient in exerting its tumor suppressive activity both in vitro and in vivo. PLoS One, 6(9), e25547.PubMedCentralPubMedCrossRef
101.
Chen, L., Liu, C., Ko, F. C., Xu, N., Ng, I. O., Yam, J. W., et al. (2012). Solution structure of the phosphotyrosine binding (PTB) domain of human tensin2 protein in complex with deleted in liver cancer 1 (DLC1) peptide reveals a novel peptide binding mode. Journal of Biological Chemistry, 287(31), 26104–26114.PubMedCentralPubMedCrossRef
102.
Zaidel-Bar, R., Cohen, M., Addadi, L., & Geiger, B. (2004). Hierarchical assembly of cell-matrix adhesion complexes. Biochemical Society Transactions, 32(3), 416–420.PubMedCrossRef
103.
Lo, S. H. (2004). Tensin. International Journal of Biochemistry and Cell Biology, 36(1), 31–34.PubMedCrossRef
104.
Chen, H., Duncan, I. C., Bozorgchami, H., & Lo, S. H. (2002). Tensin1 and a previously undocumented family member, tensin2, positively regulate cell migration. Proceedings of the National Academy of Sciences of the United States of America, 99(2), 733–738.PubMedCentralPubMedCrossRef
105.
Chen, H., & Lo, S. H. (2003). Regulation of tensin-promoted cell migration by its focal adhesion binding and Src homology domain 2. Biochemistry Journal, 370(3), 1039–1045.CrossRef
106.
Calderwood, D. A., Fujioka, Y., de Pereda, J. M., Garcia-Alvarez, B., Nakamoto, T., Margolis, B., et al. (2003). Integrin β cytoplasmic domain interactions with phosphotyrosine-binding domains: a structural prototype for diversity in integrin signaling. Proceedings of the National Academy of Sciences of the United States of America, 100(5), 2272–2277.PubMedCentralPubMedCrossRef
107.
Schaller, M. D. (2001). Paxillin: a focal adhesion-associated adaptor protein. Oncogene, 20(44), 6459–6472.PubMedCrossRef
108.
West, K. A., Zhang, H., Brown, M. C., Nikolopoulos, S. N., Riedy, M. C., Horwitz, A. F., et al. (2001). The LD4 motif of paxillin regulates cell spreading and motility through an interaction with paxillin kinase linker (PKL). Journal of Cell Biology, 154(1), 161–176.PubMedCentralPubMedCrossRef
109.
Li, Y., & Cozzi, P. J. (2007). Targeting uPA/uPAR in prostate cancer. Cancer Treatment Reviews, 33(6), 521–527.PubMedCrossRef
110.
Czekay, R. P., & Loskutoff, D. J. (2009). Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism. Journal of Cellular Physiology, 220(3), 655–663.PubMedCentralPubMedCrossRef
111.
Czekay, R. P., Aertgeerts, K., Curriden, S. A., & Loskutoff, D. J. (2003). Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. Journal of Cell Biology, 160(5), 781–791.PubMedCentralPubMedCrossRef
112.
Czekay, R. P., Wilkins-Port, C. E., Higgins, S. P., Freytag, J., Overstreet, J. M., Klein, R. M., et al. (2011). PAI-1: an integrator of cell signaling and migration. International Journal of Cell Biology, 2011562481.
113.
Paszek, M. J., Zahir, N., Johnson, K. R., Lakins, J. N., Rozenberg, G. I., Gefen, A., et al. (2005). Tensional homeostasis and the malignant phenotype. Cancer Cell, 8(3), 241–254.PubMedCrossRef
114.
Stewart, D. A., Cooper, C. R., & Sikes, R. A. (2004). Changes in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancer. Reproductive Biology and Endocrinology, 22.
115.
Deryugina, E. I., & Quigley, J. P. (2006). Matrix metalloproteinases and tumor metastasis. Cancer and Metastasis Reviews, 25(1), 9–34.PubMedCrossRef
116.
Wai, P. Y., & Kuo, P. C. (2004). The role of Osteopontin in tumor metastasis. Journal of Surgical Research, 121(2), 228–241.PubMedCrossRef
117.
Navarro, A., Anand-Apte, B., & Parat, M. O. (2004). A role for caveolae in cell migration. FASEB Journal, 18(15), 1801–1811.PubMedCrossRef
118.
Wei, Y., Yang, X., Liu, Q., Wilkins, J. A., & Chapman, H. A. (1999). A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. Journal of Cell Biology, 144(6), 1285–1294.PubMedCentralPubMedCrossRef
119.
Puyraimond, A., Fridman, R., Lemesle, M., Arbeille, B., & Menashi, S. (2001). MMP-2 colocalizes with caveolae on the surface of endothelial cells. Experimental Cell Research, 262(1), 28–36.PubMedCrossRef
120.
Isshiki, M., Ando, J., Yamamoto, K., Fujita, T., Ying, Y., & Anderson, R. G. (2002). Sites of Ca(2+) wave initiation move with caveolae to the trailing edge of migrating cells. Journal of Cell Science, 115(3), 475–484.PubMed
121.
Yamaga, M., Sekimata, M., Fujii, M., Kawai, K., Kamata, H., Hirata, H., et al. (2004). A PLCδ1-binding protein, p122/RhoGAP, is localized in caveolin-enriched membrane domains and regulates caveolin internalization. Genes to Cells, 9(1), 25–37.PubMedCrossRef
122.
Liu, G., Grant, W. M., Persky, D., Latham, V. M., Jr., Singer, R. H., & Condeelis, J. (2002). Interactions of elongation factor 1α with F-actin and β-actin mRNA: implications for anchoring mRNA in cell protrusions. Molecular Biology of the Cell, 13(2), 579–592.PubMedCentralPubMedCrossRef
123.
Gross, S. R., & Kinzy, T. G. (2005). Translation elongation factor 1α is essential for regulation of the actin cytoskeleton and cell morphology. Nature Structural and Molecular Biology, 12(9), 772–778.PubMedCrossRef
124.
Zhang, J., Guo, H., Mi, Z., Gao, C., Bhattacharya, S., Li, J., et al. (2009). EF1A1-actin interactions alter mRNA stability to determine differential osteopontin expression in HepG2 and Hep3B cells. Experimental Cell Research, 315(2), 304–312.PubMedCrossRef
125.
Hu, K. Q., & Settleman, J. (1997). Tandem SH2 binding sites mediate the RasGAP-RhoGAP interaction: a conformational mechanism for SH3 domain regulation. EMBO Journal, 16(3), 473–483.PubMedCentralPubMedCrossRef
126.
Bradley, W. D., Hernandez, S. E., Settleman, J., & Koleske, A. J. (2006). Integrin signaling through Arg activates p190RhoGAP by promoting its binding to p120RasGAP and recruitment to the membrane. Molecular Biology of the Cell, 17(11), 4827–4836.PubMedCentralPubMedCrossRef
127.
Akagi, I., Okayama, H., Schetter, A. J., Robles, A. I., Kohno, T., Bowman, E. D., et al. (2013). Combination of Protein Coding and Noncoding Gene Expression as a Robust Prognostic Classifier in Stage I Lung Adenocarcinoma. Cancer Research, 73(13), 3821–3832.PubMedCrossRef
128.
Ullmannova, V., & Popescu, N. C. (2007). Inhibition of cell proliferation, induction of apoptosis, reactivation of DLC1, and modulation of other gene expression by dietary flavone in breast cancer cell lines. Cancer Detection and Prevention, 31(2), 110–118.PubMedCentralPubMedCrossRef
129.
Nagaraja, G. M., & Kandpal, R. P. (2004). Chromosome 13q12 encoded Rho GTPase activating protein suppresses growth of breast carcinoma cells, and yeast two-hybrid screen shows its interaction with several proteins. Biochemical and Biophysical Research Communications, 313(3), 654–665.PubMedCrossRef
130.
Leung, T. H., Ching, Y. P., Yam, J. W., Wong, C. M., Yau, T. O., Jin, D. Y., et al. (2005). Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proceedings of the National Academy of Sciences of the United States of America, 102(42), 15207–15212.PubMedCentralPubMedCrossRef
131.
Lin, Y., Chen, N. T., Shih, Y. P., Liao, Y. C., Xue, L., & Lo, S. H. (2010). DLC2 modulates angiogenic responses in vascular endothelial cells by regulating cell attachment and migration. Oncogene, 29(20), 3010–3016.PubMedCentralPubMedCrossRef
132.
Ng, D. C., Chan, S. F., Kok, K. H., Yam, J. W., Ching, Y. P., Ng, I. O., et al. (2006). Mitochondrial targeting of growth suppressor protein DLC2 through the START domain. FEBS Letters, 580(1), 191–198.PubMedCrossRef
133.
Ching, Y. P., Wong, C. M., Chan, S. F., Leung, T. H., Ng, D. C., Jin, D. Y., et al. (2003). Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. Journal of Biological Chemistry, 278(12), 10824–10830.PubMedCrossRef
134.
Barras, D., Lorusso, G., Rüegg, C., & Widmann, C. (2013). Inhibition of cell migration and invasion by the TAT-RasGAP317-326 peptide requires the DLC1 tumor suppressor. Oncogene. doi:10.​1038/​onc.​2013.​465.
Metadaten
Titel
GAP-independent functions of DLC1 in metastasis
verfasst von
David Barras
Christian Widmann
Publikationsdatum
01.03.2014
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 1/2014
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-013-9458-0

Weitere Artikel der Ausgabe 1/2014

Cancer and Metastasis Reviews 1/2014 Zur Ausgabe

NON-THEMATIC REVIEW

Netrin-1 as a potential target for metastatic cancer: focus on colorectal cancer

NON-THEMATIC REVIEW

The promise of sonodynamic therapy

NON-THEMATIC REVIEW

The dual functions of YAP-1 to promote and inhibit cell growth in human malignancy

NON-THEMATIC REVIEW

Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine

Clinical

Bone metastases in hepatocellular carcinoma: an emerging issue

OriginalPaper

Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise